{
  "timestamp": "20250714_1728",
  "records": [
    {
      "file": "human-exposure-to-bisphenol-a.pdf",
      "LLM_challenge_level": 1,
      "passes": 73,
      "total": 77,
      "pass_rate": 94.81,
      "failures": [
        {
          "question_id": 1,
          "question_text": "Provide a descriptive title using normal language without technical terms or acronyms.",
          "answer_text": "Human Exposure to Bisphenol A in Europe: Understanding Risks and Sources"
        },
        {
          "question_id": 3,
          "question_text": "Which toxicological target (organ, tissue, physiological/biochemical function, etc.) is modelled? (8.1)",
          "answer_text": "The toxicological targets associated with Bisphenol A (BPA) include the reproductive system, the immune system, and various physiological functions such as cognitive function and metabolism. BPA is known to disrupt the normal functioning of the hormone system, which can lead to adverse effects on reproductive function and mammary gland development, as well as potential impacts on immune responses and metabolic processes _(Source: human-exposure-to-bisphenol-a.pdf)_."
        },
        {
          "question_id": 6,
          "question_text": "To which (human) adverse outcome(s) is your test method related or could be related? (8.1; 9.2; 9.3)",
          "answer_text": "The assay related to human exposure to Bisphenol A (BPA) is associated with several adverse health outcomes. BPA is known to harm human health due to its properties as an endocrine disruptor, which can alter hormone system functions. Specific adverse outcomes include:\n\n1. Damage to the reproductive system.\n2. Negative effects on the immune system.\n3. Disruption of reproductive function.\n4. Impacts on mammary gland development.\n5. Effects on cognitive function and metabolism.\n\nThese health risks arise from exposure to unsafe levels of BPA, as indicated by the detection of BPA in the urine of a significant percentage of the population in Europe, with levels exceeding safety thresholds set by health authorities _(Source: human-exposure-to-bisphenol-a.pdf)_."
        },
        {
          "question_id": 7,
          "question_text": "Which hazard(s) do(es) your test method (potentially) predict? (8.1; 8.6)",
          "answer_text": "The assay potentially predicts hazards related to human health due to exposure to Bisphenol A (BPA). Specifically, it identifies BPA as a hazardous chemical that can damage fertility, cause serious eye damage, allergic skin reactions, and respiratory irritation. Additionally, BPA is classified as an endocrine disruptor, which can disrupt the normal functioning of the hormone system, affecting reproductive function, mammary gland development, cognitive function, and metabolism _(Source: human-exposure-to-bisphenol-a.pdf)_."
        }
      ]
    },
    {
      "file": "seasonal-influenza-annual-epidemiological-report-2023-2024.pdf",
      "LLM_challenge_level": 1,
      "passes": 75,
      "total": 77,
      "pass_rate": 97.4,
      "failures": [
        {
          "question_id": 1,
          "question_text": "Provide a descriptive title using normal language without technical terms or acronyms.",
          "answer_text": "The 2023-2024 Seasonal Influenza Report: Overview of Flu Activity and Vaccine Effectiveness in Europe"
        },
        {
          "question_id": 12,
          "question_text": "This only applies to updated versions. If this is the original version, state 'original version'.",
          "answer_text": "original version"
        }
      ]
    },
    {
      "file": "DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf",
      "LLM_challenge_level": 2,
      "passes": 62,
      "total": 77,
      "pass_rate": 80.52,
      "failures": [
        {
          "question_id": 1,
          "question_text": "Provide a descriptive title using normal language without technical terms or acronyms.",
          "answer_text": "The Impact of Dimethyl Sulfoxide on Human Cell Functions and Genetic Changes in Laboratory Studies."
        },
        {
          "question_id": 3,
          "question_text": "Which toxicological target (organ, tissue, physiological/biochemical function, etc.) is modelled? (8.1)",
          "answer_text": "The assay models the effects of DMSO on human cardiac and hepatic microtissues. Specifically, it evaluates the impact of DMSO on the transcriptome, proteome, and DNA methylation profiles in these tissues, indicating its effects on cellular processes and epigenetic landscape in both cardiac and hepatic models _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_."
        },
        {
          "question_id": 4,
          "question_text": "Which test system and readout(s) are used? (4.1; 5.2)",
          "answer_text": "The assay utilizes human 3D microtissues (MTs) as the test system, specifically a maturing iPSC-derived cardiac model and a mature hepatic model. The readouts include transcriptome analysis (using ribo-depleted total RNA sequencing and microRNA sequencing), whole-genome methylation profiling (using MeDIP-seq), and proteomics analysis (using mass spectrometry) to assess the effects of DMSO exposure on cellular processes and epigenetic landscape _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_."
        },
        {
          "question_id": 5,
          "question_text": "Which biological process(es) (e.g. neurite outgrowth, differentiation) and/or toxicological events (e.g. oxidative stress, cell death) are modelled/reflected by your test method? (8.1)",
          "answer_text": "The assay models several biological processes and toxicological events, particularly focusing on the effects of DMSO on human cellular processes. Key biological processes affected include:\n\n1. **Gene Expression Regulation**: DMSO exposure led to significant changes in gene expression, with 2,051 differentially expressed genes (DEGs) identified in cardiac microtissues and 2,711 DEGs in hepatic microtissues, indicating alterations in cellular processes related to gene regulation _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n2. **MicroRNA Deregulation**: The assay revealed large-scale deregulations of microRNAs, particularly in cardiac microtissues, which can impact gene silencing and regulatory functions within the cells _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n3. **Epigenetic Changes**: DMSO induced significant alterations in the epigenetic landscape, particularly affecting DNA methylation patterns in cardiac microtissues, which can influence gene expression and cellular function _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n4. **Cellular Metabolism**: Pathway analysis indicated that DMSO exposure affected metabolic processes, including the citric acid cycle and glucose metabolism, which are crucial for cellular energy production _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n5. **Cellular Responses to Stress**: The assay also highlighted changes in pathways related to cellular responses to stress, indicating that DMSO exposure may induce stress-related cellular events _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\nOverall, the assay reflects a range of biological processes and toxicological events, including gene expression regulation, microRNA deregulation, epigenetic modifications, metabolic alterations, and stress responses."
        },
        {
          "question_id": 6,
          "question_text": "To which (human) adverse outcome(s) is your test method related or could be related? (8.1; 9.2; 9.3)",
          "answer_text": "The assay related to DMSO exposure could be associated with several adverse outcomes in humans, particularly concerning embryonic development and potential long-term health effects. The study indicates that DMSO induces significant alterations in microRNA expression and epigenetic landscape, especially in maturing cardiac microtissues. These changes may impact cellular processes critical for development, potentially leading to adverse outcomes such as:\n\n1. **Impaired Embryonic Development**: The extreme changes in microRNAs and alterations in the epigenetic landscape suggest that DMSO is not biologically inert and may disrupt normal embryonic development, particularly when used in cryopreservation of embryos and oocytes _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n2. **Increased Risk of Birth Defects**: The study highlights concerns regarding the use of DMSO in assisted reproductive technologies, as it may contribute to an increased risk of birth defects in children conceived through these methods _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n3. **Long-term Health Consequences**: The potential for persistent epigenetic changes due to DMSO exposure raises concerns about long-term health outcomes, including cardiovascular and metabolic risks, which may manifest later in life for individuals conceived through assisted reproductive technologies _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\nThese adverse outcomes underscore the need for caution in the use of DMSO, particularly in contexts involving human development and reproductive health."
        },
        {
          "question_id": 7,
          "question_text": "Which hazard(s) do(es) your test method (potentially) predict? (8.1; 8.6)",
          "answer_text": "The assay evaluates the biological effects of DMSO on human cellular processes and the epigenetic landscape, particularly focusing on its impact on gene expression, microRNA regulation, and DNA methylation. The findings suggest that DMSO can induce drastic changes in cellular processes, which may lead to potential hazards such as:\n\n1. **Altered Gene Expression**: The assay identified over 2000 differentially expressed genes in both cardiac and hepatic microtissues, indicating that DMSO exposure can disrupt normal gene regulation, which may lead to adverse biological effects _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n2. **MicroRNA Deregulation**: The assay revealed significant changes in microRNA profiles, particularly in cardiac microtissues, which could affect gene silencing mechanisms and lead to further dysregulation of cellular functions _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n3. **Epigenetic Alterations**: The assay demonstrated that DMSO exposure resulted in genome-wide changes in DNA methylation patterns, particularly hypermethylation in cardiac microtissues. Such epigenetic modifications can have long-term consequences on gene expression and cellular behavior, potentially leading to developmental issues or diseases _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\nThese hazards highlight the need for caution in the use of DMSO, especially in applications involving cryopreservation of embryos and oocytes, as they may impact embryonic development and long-term health outcomes _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_."
        },
        {
          "question_id": 12,
          "question_text": "This only applies to updated versions. If this is the original version, state 'original version'.",
          "answer_text": "Original version."
        },
        {
          "question_id": 14,
          "question_text": "Include affiliation.",
          "answer_text": "The assay \"DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro\" is associated with the following affiliations:\n\n1. Toxicogenomics, Maastricht University, Maastricht, Netherlands.\n2. Computational Molecular Biology, Max-Planck-Institute for Molecular Genetics, Berlin, Germany.\n3. F. Hoffmann-La Roche AG, Basel, Switzerland.\n4. Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich, Switzerland.\n5. Genedata AG, Basel, Switzerland.\n6. Genetics and Cell Biology, Maastricht University, Medical Center, Maastricht, Netherlands. \n\nThese affiliations represent the institutions involved in the research and analysis conducted in the study _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_."
        },
        {
          "question_id": 18,
          "question_text": "Describe briefly whether the cells are from a commercial supplier, continuously generated by cell culture, or obtained by isolation from human/animal tissue (or other).",
          "answer_text": "The cells used in the assay are derived from a commercial supplier. Specifically, the 3D InSight\u2122 Human Cardiac Microtissues contain a co-culture of iPSC-derived human cardiomyocytes from a single female Caucasian donor and cardiac fibroblasts from an 18-year-old Caucasian male. The 3D InSight\u2122 Human Liver Microtissues consist of approximately 1000 primary human hepatocytes pooled from a multi-donor source (5 males and 5 females aged between 7-59 years) in co-culture with primary human Kupffer cells from a 27-year-old Caucasian individual of unreported gender _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_."
        },
        {
          "question_id": 19,
          "question_text": "Give a brief overview of your biological source system, i.e. the source or starting cells that you use. Which cell type(s) are used or obtained (e.g. monoculture/co-culture, differentiation state, 2D/3D, etc.)? If relevant, give human donor specifications (e.g. sex, age, pool of 10 donors, from healthy tissue, etc.).",
          "answer_text": "The biological source system used in the assay consists of 3D microtissues (MTs) derived from human cells. Specifically, the cardiac microtissues are composed of approximately 4,000 iPSC-derived human cardiomyocytes from a single female Caucasian donor with no known disease phenotype, co-cultured with 1,000 cardiac fibroblasts from an 18-year-old Caucasian male. The hepatic microtissues are made up of approximately 1,000 primary human hepatocytes pooled from 10 male and female donors aged between 7 to 59 years, co-cultured with 1,000 primary human Kupffer cells from a 27-year-old Caucasian individual of unreported gender. This setup allows for a 3D culture environment, which is essential for mimicking in vivo conditions more closely than traditional 2D cultures _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_."
        },
        {
          "question_id": 25,
          "question_text": "Describe the test system as it is used in the test. If the generation of the test system involves differentiation steps or complex technical manipulation (e.g. formation of microtissues), this is described in 3.6. Give details on the general features/principles of the culture protocol (collagen embedding, 3D structuring, addition of mitotic inhibitors, addition of particular hormones/growth factors, etc.) of the cells that are used for the test. What is the percentage of contaminating cells; in co-cultures what is the percentage of each subpopulation? Are there subpopulations that are generally more sensitive to cytotoxicity than others, and could this influence viability measures? Is it known whether specific chemicals/chemical classes show differential cytotoxicity for the cell sub-populations used?",
          "answer_text": "The test system involves the use of 3D microtissues (MTs) derived from human cells, specifically a maturing cardiac model and a mature hepatic model. The cardiac microtissues are composed of approximately 4,000 iPSC-derived human cardiomyocytes from a single female donor, co-cultured with 1,000 cardiac fibroblasts from an 18-year-old male. The hepatic microtissues consist of around 1,000 primary human hepatocytes pooled from 10 male and female donors aged between 7 and 59 years, co-cultured with 1,000 primary human Kupffer cells from a 27-year-old Caucasian individual of unreported gender. \n\nThe culture protocol for these microtissues includes embedding in a 3D matrix, which allows for the formation of a more physiologically relevant environment compared to traditional 2D cultures. The microtissues are maintained in specific culture media designed for cardiac and hepatic cells, respectively. The protocol does not specify the use of mitotic inhibitors or particular hormones/growth factors, but the 3D structuring itself is a critical aspect of the culture method.\n\nRegarding the percentage of contaminating cells, the document does not provide specific percentages for contaminating cells or the exact composition of each subpopulation in the co-cultures. However, it is noted that the cardiac model is derived from a single donor, which may introduce variability in sensitivity to cytotoxicity due to genetic factors. \n\nIt is suggested that certain subpopulations, such as cardiomyocytes, may be more sensitive to cytotoxicity than others, potentially influencing viability measures. The document does not provide specific information on whether certain chemicals or chemical classes exhibit differential cytotoxicity for the cell sub-populations used in the test. \n\nOverall, the test system is designed to mimic in vivo conditions more closely, which may affect the responses of the cell populations to cytotoxic agents, but detailed quantitative data on subpopulation sensitivity and chemical interactions are not available in the provided context. \n\n_(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_"
        },
        {
          "question_id": 31,
          "question_text": "Give information on where the test system differs from the mimicked human tissue and which gaps of analogy need to be considered.",
          "answer_text": "The assay involves the use of 3D microtissues (MTs) derived from human cells, specifically a maturing iPSC-derived cardiac model and a mature hepatic model. The differences between these test systems and actual human tissues include:\n\n1. **Developmental Stage**: The cardiac microtissues are derived from induced pluripotent stem cells (iPSCs) and represent a fetal-like phenotype rather than fully mature adult cardiomyocytes. This may affect their response to DMSO and other treatments, as fetal cells can behave differently compared to adult cells in terms of metabolism and gene expression _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n2. **Cell Composition**: The cardiac MTs are co-cultured with fibroblasts from a single donor, while the hepatic MTs consist of primary human hepatocytes pooled from multiple donors. This single-donor model for cardiac MTs may introduce genotype sensitivity, which could lead to variability in responses that may not be representative of a broader population _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n3. **Tissue-Specific Responses**: The assay demonstrated that cardiac microtissues showed a greater susceptibility to DMSO effects compared to hepatic microtissues. This indicates that the biological responses may not be directly translatable between different tissue types, and the specific cellular processes affected by DMSO may vary significantly _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n4. **Epigenetic Landscape**: The assay revealed significant alterations in the epigenetic landscape of cardiac microtissues, which were not observed in hepatic microtissues. This suggests that the epigenetic responses to DMSO exposure are tissue-specific and may not reflect the behavior of actual human tissues in vivo _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\nThese gaps in analogy highlight the need for caution when extrapolating findings from the assay to human physiology, particularly in the context of drug toxicity and developmental impacts."
        },
        {
          "question_id": 35,
          "question_text": "Define the specific endpoint(s) of the test system that you use for toxicity testing (e.g. cytotoxicity, cell migration, etc.). Indicate whether cytotoxicity is the primary endpoint. What are secondary/further endpoints? Also describe here potential reference/normalization endpoints (e.g. cytotoxicity, protein content, housekeeping gene expression) that are used for normalization of the primary endpoint.",
          "answer_text": "The assay evaluates the biological effects of dimethyl sulfoxide (DMSO) on human cellular processes, specifically focusing on the following endpoints:\n\n1. **Primary Endpoint:**\n   - **Cytotoxicity** is the primary endpoint, assessed through the analysis of differentially expressed genes (DEGs) and changes in cellular processes in response to DMSO exposure.\n\n2. **Secondary/Further Endpoints:**\n   - **MicroRNA Expression:** The assay examines the deregulation of microRNAs in both cardiac and hepatic microtissues.\n   - **DNA Methylation Patterns:** The assay investigates genome-wide changes in DNA methylation, particularly in cardiac microtissues, to assess epigenetic alterations.\n   - **Proteome Analysis:** The assay includes proteomics to evaluate changes in protein expression levels in response to DMSO.\n\n3. **Potential Reference/Normalization Endpoints:**\n   - **Housekeeping Gene Expression:** Normalization of gene expression data can be performed using housekeeping genes to ensure that variations in expression levels are not due to differences in sample input.\n   - **Protein Content:** Total protein content may be used for normalization in proteomics analysis to account for variations in sample loading.\n\nThese endpoints collectively provide a comprehensive assessment of the effects of DMSO on cellular health and function, indicating that cytotoxicity is the primary focus while also considering epigenetic and molecular changes as secondary endpoints _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_."
        },
        {
          "question_id": 36,
          "question_text": "Define and describe the principle(s) of the analytical methods used. Provide here a general overview of the method\u2019s key steps (e.g. cells are fixed or not, homogenized sample or not, etc.), sufficient for reviewers/regulators to understand what was done, but not in all detail for direct repetition. If you have two or more endpoints (e.g. viability and neurite outgrowth), do you measure both in the same well, under same conditions in parallel, or independently of each other? For imaging endpoints: Explain in general how quantification algorithm or how semi-quantitative estimates are obtained and how many cells are imaged (roughly).",
          "answer_text": "The analytical methods used in the assay involve several key techniques to assess the effects of DMSO on human cellular processes and the epigenetic landscape. The main methods employed include transcriptome analysis, microRNA sequencing, proteomics analysis, and whole-genome methylation profiling. Here is a general overview of the key steps involved in these methods:\n\n1. **Sample Preparation**: Human 3D microtissues (MTs) of cardiac and hepatic origin are cultured and exposed to either medium with or without 0.1% DMSO for two weeks. Samples are collected at multiple time points (2, 8, 24, 72, 168, 240, and 336 hours) in triplicate to ensure reproducibility.\n\n2. **RNA Sequencing**: Total RNA is isolated from the microtissues using a specialized kit. The RNA is then depleted of ribosomal RNA and prepared for sequencing. The sequencing is performed using paired-end reads, and quality control measures are taken to ensure the integrity of the data.\n\n3. **MicroRNA Sequencing**: A portion of the isolated total RNA is used for miRNA sequencing. The samples undergo library preparation and are sequenced similarly to the RNA sequencing process, with specific focus on small RNA species.\n\n4. **Proteomics Analysis**: Proteins are extracted from the microtissues, and mass spectrometry is used to analyze the proteome. This involves quantifying approximately 2,000 proteins to assess changes in protein expression due to DMSO exposure.\n\n5. **Methylation Profiling**: Whole-genome methylation profiling is conducted using MeDIP-seq. DNA is fragmented, and methylated fragments are captured using specific antibodies. The resulting libraries are sequenced to identify differentially methylated regions (DMRs).\n\n6. **Data Analysis**: The data from RNA sequencing, microRNA sequencing, and proteomics are analyzed to identify differentially expressed genes (DEGs), differentially expressed miRNAs, and differentially methylated regions. Pathway analysis is performed to understand the biological processes affected by DMSO.\n\nIn terms of endpoints, the assay measures multiple outcomes, including gene expression, microRNA expression, protein levels, and DNA methylation changes. These measurements are conducted independently of each other, with specific samples allocated for each type of analysis.\n\nFor imaging endpoints, while the assay primarily focuses on molecular analyses rather than direct imaging, any imaging that may be involved in assessing cellular morphology or other characteristics would typically involve quantification algorithms that analyze the images to provide semi-quantitative estimates of the observed effects. The number of cells imaged would depend on the specific imaging protocol used, but generally, a substantial number of cells would be analyzed to ensure statistical relevance.\n\nOverall, the combination of these analytical methods provides a comprehensive understanding of the biological effects of DMSO on human cellular processes and the epigenetic landscape in vitro. The results highlight the significant impact of DMSO, particularly in cardiac microtissues, indicating that DMSO is not biologically inert and can induce substantial changes in cellular function and gene regulation."
        },
        {
          "question_id": 60,
          "question_text": "What is the scientific rationale to link test method data to a relevant in vivo adverse outcome? Which toxicological target (organ, tissue, physiological/biochemical function, etc.) is modelled? Which biological process(es) (e.g. neurite outgrowth, differentiation) are modelled/reflected by your test method? Which toxicological events (e.g. oxidative stress, cell death) are modelled/reflected by your test method? To which (human) adverse outcome(s) is your test method related? Which hazard(s) do(es) your test method (potentially) predict?",
          "answer_text": "The assay \"DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro\" evaluates the biological effects of dimethyl sulfoxide (DMSO) on human cellular processes, particularly focusing on cardiac and hepatic microtissues. \n\n1. **Scientific Rationale to Link Test Method Data to Relevant In Vivo Adverse Outcomes:** The rationale is based on the observation that DMSO, commonly used as a solvent in biological assays, induces significant alterations in gene expression, microRNA profiles, and DNA methylation patterns. These changes can affect cellular processes and potentially lead to adverse outcomes in vivo, particularly in sensitive developmental stages such as embryonic development _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n2. **Toxicological Target:** The assay models cardiac and hepatic tissues, specifically focusing on the physiological and biochemical functions of these organs. The cardiac microtissues represent a maturing model of human cardiomyocytes, while the hepatic microtissues consist of mature human hepatocytes _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n3. **Biological Processes Modeled/Reflected:** The assay reflects several biological processes, including:\n   - Gene expression regulation\n   - MicroRNA biogenesis and function\n   - Cellular responses to stress\n   - Metabolic processes, particularly related to glucose and lipid metabolism _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n4. **Toxicological Events Modeled/Reflected:** The assay models several toxicological events, including:\n   - Oxidative stress, as indicated by changes in mitochondrial pathways linked to reactive oxygen species (ROS) production\n   - Cell death mechanisms, as inferred from alterations in cellular metabolism and ATP production _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n5. **Human Adverse Outcomes Related to the Test Method:** The test method is related to potential adverse outcomes such as impaired embryonic development, reduced viability of embryos and oocytes, and possible long-term health effects due to epigenetic alterations. These outcomes are particularly relevant in the context of assisted reproductive technologies _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_.\n\n6. **Hazards Potentially Predicted by the Test Method:** The assay potentially predicts hazards related to:\n   - Developmental toxicity due to epigenetic changes\n   - Impaired cellular function and viability in cardiac and hepatic tissues\n   - Risks associated with the use of DMSO in cryopreservation and other biomedical applications _(Source: DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitr.pdf)_."
        }
      ]
    },
    {
      "file": "application of the virtual cell based assay for simulation-KJNA28694ENN.pdf",
      "LLM_challenge_level": 2,
      "passes": 65,
      "total": 77,
      "pass_rate": 84.42,
      "failures": [
        {
          "question_id": 1,
          "question_text": "Provide a descriptive title using normal language without technical terms or acronyms.",
          "answer_text": "A Virtual Model for Understanding How Chemicals Behave in Laboratory Tests After Short Exposure"
        },
        {
          "question_id": 4,
          "question_text": "Which test system and readout(s) are used? (4.1; 5.2)",
          "answer_text": "The test system used in the assay is the 3T3 BALB/c cell line, and the readout is based on the Neutral Red Uptake (NRU) cytotoxicity assay, which measures cell viability by assessing the uptake of the Neutral Red dye by living cells _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_."
        },
        {
          "question_id": 5,
          "question_text": "Which biological process(es) (e.g. neurite outgrowth, differentiation) and/or toxicological events (e.g. oxidative stress, cell death) are modelled/reflected by your test method? (8.1)",
          "answer_text": "The Virtual Cell Based Assay (VCBA) models the biological processes of cell growth and division, as well as the toxicological event of cell death. Specifically, it simulates the kinetics of a chemical tested, including the effects on cell viability and the concentration-response relationship derived from in vitro toxicity studies. The model incorporates parameters such as the No-Effect Concentration (NEC) and the Killing rate (Kr) to optimize the predictions of toxicity based on the experimental data obtained from assays like the Neutral Red Uptake cytotoxicity assay _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_."
        },
        {
          "question_id": 6,
          "question_text": "To which (human) adverse outcome(s) is your test method related or could be related? (8.1; 9.2; 9.3)",
          "answer_text": "The Virtual Cell Based Assay (VCBA) is related to assessing the risk of adverse systemic effects of chemicals, particularly in the context of acute toxicity. It aims to simulate the absorption, distribution, metabolism, and excretion (ADME) of chemicals in vitro to determine the target organ bioavailable concentration. This information can be used to compare predicted internal concentrations with effective internal concentrations derived from in vitro toxicity studies. The VCBA can help identify potential adverse outcomes related to acute oral toxicity in humans by providing insights into the bioavailable concentrations of chemicals that may lead to toxic effects _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_. \n\nHowever, specific adverse outcomes are not detailed in the provided context. Therefore, the exact human adverse outcomes related to the VCBA are not explicitly stated in the document."
        },
        {
          "question_id": 7,
          "question_text": "Which hazard(s) do(es) your test method (potentially) predict? (8.1; 8.6)",
          "answer_text": "The Virtual Cell Based Assay (VCBA) potentially predicts hazards related to acute oral toxicity of chemicals. It aims to assess the risk of adverse systemic effects by simulating the absorption, distribution, metabolism, and excretion (ADME) of chemicals in vitro, allowing for the determination of target organ bioavailable concentrations. The model helps in comparing predicted internal concentrations with effective internal concentrations derived from in vitro toxicity studies, thereby providing insights into the potential toxicity of various chemicals _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_. \n\nAdditionally, the VCBA can be used to identify compounds that may exhibit significant discrepancies between in vitro determined toxic concentrations and in vivo outcomes, which is crucial for understanding the potential hazards posed by these chemicals _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_."
        },
        {
          "question_id": 12,
          "question_text": "This only applies to updated versions. If this is the original version, state 'original version'.",
          "answer_text": "Original version."
        },
        {
          "question_id": 14,
          "question_text": "Include affiliation.",
          "answer_text": "The Virtual Cell Based Assay (VCBA) is affiliated with the Joint Research Centre (JRC) of the European Commission, specifically within the Directorate General for Health, Consumers, and Reference Materials, Chemicals Safety and Alternative Methods Unit (F.3) located in Ispra, Italy. The authors of the report include Susana Proen\u00e7a, Alicia Paini, Elisabeth Joossens, Jose Vicente Sala Benito, Elisabet Berggren, Andrew Worth, and Pilar Prieto, all associated with the JRC _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_."
        },
        {
          "question_id": 15,
          "question_text": "Provide the details of the principal contact person.",
          "answer_text": "The principal contact person for the assay is:\n\n**Name:** Pilar Prieto  \n**Address:** TP126 I-21027 Ispra (VA), Italy  \n**Email:** pilar.prieto-peraita@ec.europa.eu  \n**Tel.:** 00390332785534  \n\n_(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_"
        },
        {
          "question_id": 19,
          "question_text": "Give a brief overview of your biological source system, i.e. the source or starting cells that you use. Which cell type(s) are used or obtained (e.g. monoculture/co-culture, differentiation state, 2D/3D, etc.)? If relevant, give human donor specifications (e.g. sex, age, pool of 10 donors, from healthy tissue, etc.).",
          "answer_text": "The biological source system used in the Virtual Cell Based Assay (VCBA) is the 3T3 BALB/c cell line. This cell line is a type of mouse fibroblast cell line that is commonly used in in vitro toxicity studies. The VCBA utilizes these cells in a monoculture format, specifically in a 2D culture system. The cells are exposed to various chemicals to assess their cytotoxic effects, measured through the Neutral Red Uptake (NRU) assay. There are no specific human donor specifications provided, as the assay relies on this established mouse cell line rather than human cells _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_."
        },
        {
          "question_id": 31,
          "question_text": "Give information on where the test system differs from the mimicked human tissue and which gaps of analogy need to be considered.",
          "answer_text": "The Virtual Cell Based Assay (VCBA) differs from mimicked human tissue in several key aspects that need to be considered when interpreting results. \n\n1. **Underrepresentation of Toxicological Targets**: The VCBA does not capture the multi-organ interactions that occur in vivo, which are essential for understanding the full scope of toxicological effects. In vitro systems often lack the complexity of human tissues, which can lead to an incomplete representation of the toxicological targets present in a living organism _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_.\n\n2. **Incomplete Differentiation into Organ-Specific Phenotypes**: The cell lines used in the VCBA may not fully replicate the differentiated states of human tissues, which can affect metabolism and clearance processes. This lack of organ-specific characteristics can lead to discrepancies in how chemicals are processed compared to human tissues _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_.\n\n3. **Pharmacokinetic Processes**: While some pharmacokinetic processes, such as binding to serum proteins and lipids, are present in vitro, they do not fully mimic the complex biokinetics that occur in vivo. For example, the VCBA does not account for metabolism, which can significantly influence the fate of chemicals in a living organism _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_.\n\n4. **Dosimetry/Kinetics**: The VCBA uses concentration as the dose metric, which does not reflect the actual amount of compound per number of cells. This can lead to inaccuracies in predicting the effects of chemicals, as higher cell numbers can alter the free concentration and toxic effects observed _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_.\n\n5. **Saturation Kinetics**: The VCBA does not consider saturation kinetics, which can lead to overestimations of the bioavailable concentration of chemicals. This is particularly relevant for highly lipophilic compounds that may bind extensively to cellular components _(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_.\n\nThese gaps in analogy highlight the need for careful interpretation of VCBA results and suggest that further validation with in vivo data and more sophisticated in vitro models may be necessary to improve the predictive power of the assay."
        },
        {
          "question_id": 35,
          "question_text": "Define the specific endpoint(s) of the test system that you use for toxicity testing (e.g. cytotoxicity, cell migration, etc.). Indicate whether cytotoxicity is the primary endpoint. What are secondary/further endpoints? Also describe here potential reference/normalization endpoints (e.g. cytotoxicity, protein content, housekeeping gene expression) that are used for normalization of the primary endpoint.",
          "answer_text": "The specific endpoint of the Virtual Cell Based Assay (VCBA) used for toxicity testing is cytotoxicity, which is assessed through the optimization of the No-Effect Concentration (NEC) and the Killing Rate (Kr) based on the concentration-response curves obtained from in vitro studies. Cytotoxicity is indeed the primary endpoint of this assay.\n\nSecondary or further endpoints may include the analysis of chemical partitioning among various compartments (e.g., lipid, protein, and plastic binding) and the evaluation of the impact of these factors on the predicted internal concentrations and toxicity outcomes. \n\nFor normalization of the primary endpoint (cytotoxicity), potential reference endpoints could include protein content and cell growth metrics, which help to account for variations in cell density and viability during the assay. These normalization endpoints ensure that the cytotoxicity results are accurately interpreted in the context of the experimental conditions and cell health. \n\n_(Source: application of the virtual cell based assay for simulation-KJNA28694ENN.pdf)_"
        },
        {
          "question_id": 60,
          "question_text": "What is the scientific rationale to link test method data to a relevant in vivo adverse outcome? Which toxicological target (organ, tissue, physiological/biochemical function, etc.) is modelled? Which biological process(es) (e.g. neurite outgrowth, differentiation) are modelled/reflected by your test method? Which toxicological events (e.g. oxidative stress, cell death) are modelled/reflected by your test method? To which (human) adverse outcome(s) is your test method related? Which hazard(s) do(es) your test method (potentially) predict?",
          "answer_text": "The assay in question is the Virtual Cell Based Assay (VCBA), which simulates the in vitro chemical fate following acute exposure. \n\n1. **Scientific Rationale to Link Test Method Data to In Vivo Adverse Outcomes:** The VCBA aims to simulate absorption, distribution, metabolism, and excretion (ADME) in vivo to determine the target organ bioavailable concentration. This allows for a comparison between the predicted internal concentration and an effective internal concentration derived from in vitro toxicity studies. The rationale is that significant differences can exist between the applied nominal concentration and the in vitro bioavailable concentration, which is crucial for accurate risk assessment of adverse systemic effects of chemicals _(Source: Abstract)_.\n\n2. **Toxicological Target Modeled:** The VCBA focuses on the bioavailable concentration in target organs, which is essential for assessing systemic toxicity. The model is designed to interpret in vitro acute toxicity data and compare it with in vivo results, particularly targeting the organs affected by the chemicals being tested _(Source: Abstract)_.\n\n3. **Biological Processes Modeled/Reflected:** The VCBA reflects several biological processes, including cell growth and division, as it simulates the cell cycle phases (G1, S, G2, and M) using a Leslie Matrix. It also incorporates the dynamics of chemical partitioning within the cell, which includes uptake and excretion processes _(Source: Methodology)_.\n\n4. **Toxicological Events Modeled/Reflected:** The assay models toxicological events such as cell death and the effects of chemical partitioning on toxicity prediction. It specifically looks at how chemicals interact with cellular components and how these interactions can lead to adverse effects, including degradation and binding to lipids and proteins _(Source: Abstract, Results and Discussion)_.\n\n5. **Human Adverse Outcomes Related to the Test Method:** The VCBA is related to predicting acute oral systemic toxicity in humans. It aims to provide insights into how in vitro determined toxic concentrations may differ from in vivo outcomes, which is critical for human risk assessment _(Source: Abstract, Results and Discussion)_.\n\n6. **Hazards Potentially Predicted by the Test Method:** The VCBA potentially predicts hazards related to acute toxicity, particularly the risk of systemic effects from chemical exposure. It helps identify chemicals that may have significant discrepancies between in vitro and in vivo toxicity predictions, which is vital for regulatory assessments _(Source: Abstract, Results and Discussion)_. \n\nIn summary, the VCBA serves as a tool to bridge the gap between in vitro data and in vivo outcomes, focusing on the bioavailability of chemicals in target organs and the associated toxicological events that can lead to adverse health effects."
        }
      ]
    },
    {
      "file": "ESOTC2023.pdf",
      "LLM_challenge_level": 0,
      "passes": 77,
      "total": 77,
      "pass_rate": 100.0,
      "failures": []
    },
    {
      "file": "CELEX_52020DC0065_EN_TXT.pdf",
      "LLM_challenge_level": 0,
      "passes": 76,
      "total": 77,
      "pass_rate": 98.7,
      "failures": [
        {
          "question_id": 1,
          "question_text": "Provide a descriptive title using normal language without technical terms or acronyms.",
          "answer_text": "A European Approach to Trustworthy and Ethical Artificial Intelligence"
        }
      ]
    },
    {
      "file": "The_Burden_of_FAIRness_Metadata_Fatigue_Expanded.pdf",
      "LLM_challenge_level": 0,
      "passes": 76,
      "total": 77,
      "pass_rate": 98.7,
      "failures": [
        {
          "question_id": 1,
          "question_text": "Provide a descriptive title using normal language without technical terms or acronyms.",
          "answer_text": "A Study on the Challenges and Fatigue Experienced by Researchers Due to Metadata Requirements in Biomedical Research."
        }
      ]
    },
    {
      "file": "Optimization of cell viability assays to improve repilicability and reproducibility.pdf",
      "LLM_challenge_level": 2,
      "passes": 65,
      "total": 77,
      "pass_rate": 84.42,
      "failures": [
        {
          "question_id": 1,
          "question_text": "Provide a descriptive title using normal language without technical terms or acronyms.",
          "answer_text": "Optimizing Cell Viability Tests to Enhance Consistency and Reliability in Cancer Drug Research"
        },
        {
          "question_id": 4,
          "question_text": "Which test system and readout(s) are used? (4.1; 5.2)",
          "answer_text": "The assay utilizes human breast cancer cell lines (specifically HCC38, MCF7, MCF-10A, and MDA-MB-436) as the test system. The readout for the assay is based on the resazurin reduction assay, which measures cell viability through absorbance or fluorescence after treatment with pharmaceutical agents (bortezomib, cisplatin, and carboplatin) for a specified duration (typically 24 hours) _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_."
        },
        {
          "question_id": 5,
          "question_text": "Which biological process(es) (e.g. neurite outgrowth, differentiation) and/or toxicological events (e.g. oxidative stress, cell death) are modelled/reflected by your test method? (8.1)",
          "answer_text": "The assay primarily models the toxicological event of cell death in response to cancer drug treatments. It evaluates the cytotoxic effects of pharmaceutical agents, specifically focusing on the viability of breast cancer cell lines (MCF7 and HCC38) when exposed to drugs such as bortezomib, cisplatin, and carboplatin. The assay measures cell viability through the resazurin reduction assay, which reflects the metabolic activity of cells and indicates cell death as a result of drug exposure _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_."
        },
        {
          "question_id": 9,
          "question_text": "If the method has undergone some form of validation/evaluation, give its status. (9.4)",
          "answer_text": "The assay has undergone validation, as indicated by the determination of IC50, GR50, and GRmax values for various breast cancer cell lines (MCF7, HCC38, MCF-10A, and MDA-MB-436) exposed to bortezomib or cisplatin. The optimized assay performed well across these cell lines, with data points meeting recommended quality control metrics (Z-factor, signal window, and coefficient of variation) for assay robustness. The majority of data points showed Z-factor > 0.75, signal window > 10, and coefficient of variation < 5%, indicating a high level of reproducibility and reliability in the assay results _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_."
        },
        {
          "question_id": 11,
          "question_text": "Provide the original deposition date of first version and date of current version.",
          "answer_text": "The original deposition date of the first version is November 19, 2019, and the date of the current version is February 25, 2020 _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_."
        },
        {
          "question_id": 12,
          "question_text": "This only applies to updated versions. If this is the original version, state 'original version'.",
          "answer_text": "Original version."
        },
        {
          "question_id": 18,
          "question_text": "Describe briefly whether the cells are from a commercial supplier, continuously generated by cell culture, or obtained by isolation from human/animal tissue (or other).",
          "answer_text": "The cells used in the assay are human breast cancer cell lines (HCC38, MCF7, MCF-10A, and MDA-MB-436) that were purchased from the American Type Culture Collection (ATCC) _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_."
        },
        {
          "question_id": 19,
          "question_text": "Give a brief overview of your biological source system, i.e. the source or starting cells that you use. Which cell type(s) are used or obtained (e.g. monoculture/co-culture, differentiation state, 2D/3D, etc.)? If relevant, give human donor specifications (e.g. sex, age, pool of 10 donors, from healthy tissue, etc.).",
          "answer_text": "The assay utilizes human breast cancer cell lines, specifically HCC38, MCF7, MCF-10A, and MDA-MB-436. These cell lines are maintained in a 2D monoculture system and are derived from breast tissue. The cells are cultured at 37 \u00b0C in a humidified 5% CO2 environment using various growth media supplemented with fetal bovine serum (FBS) or other specific supplements depending on the cell line. The study does not specify human donor details such as sex, age, or health status for these cell lines, as they are established cell lines rather than primary cells from human donors _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_."
        },
        {
          "question_id": 28,
          "question_text": "Give known causes of variability for final test system state. Indicate critical consumables or batch effects (e.g. plate format and supplier, batch effects of FCS or serum replacement, additives). Indicate critical handling steps, and/or influencing factors identified (e.g. special care needed in pipetting, steps that need to be performed quickly, cell density). Indicate positive and negative controls and their expected values, and accepted deviation within and between the test repeats. Give recommendations to increase/ensure reproducibility and performance.",
          "answer_text": "The assay described in the document focuses on optimizing cell viability assays to improve replicability and reproducibility in cancer drug sensitivity screens. Here are the known causes of variability for the final test system state, along with critical consumables, handling steps, controls, and recommendations for increasing reproducibility:\n\n### Known Causes of Variability\n1. **Pharmaceutical Drug Choice**: Variability is primarily associated with the type of drug used _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n2. **Cell Line**: Different cell lines exhibit varying responses to drugs, contributing to variability _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n3. **Growth Medium**: The type and composition of the growth medium, including serum concentration, can affect cell viability _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n4. **Assay Incubation Time**: The duration of drug exposure can influence the results _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n5. **DMSO Concentration**: The solvent used for drug dissolution (DMSO) can have cytotoxic effects, impacting cell viability _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n6. **Evaporation**: Evaporation rates can vary based on the plate format and sealing method, affecting drug concentration and cell viability _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n7. **Edge Effects**: Variability can arise from differences in cell viability measurements between wells located at the edges versus those in the center of the plate _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n\n### Critical Consumables or Batch Effects\n- **Plate Format and Supplier**: The choice of 96-well plates (e.g., flat-bottom vs. PCR plates) can influence evaporation rates and assay performance _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n- **Fetal Bovine Serum (FBS)**: Batch effects of FBS can lead to variability in cell growth and drug response _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n- **Additives**: The presence of antibiotics or other supplements in the growth medium can also affect cell viability and drug response _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n\n### Critical Handling Steps and Influencing Factors\n- **Pipetting**: Special care is needed in pipetting to avoid introducing variability, especially when preparing dilutions or transferring cells _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n- **Timing**: Steps that need to be performed quickly include adding drugs and resazurin to minimize variability due to evaporation or degradation _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n- **Cell Density**: Maintaining an optimal cell density (e.g., 7.5 \u00d7 10^3 cells per well) is crucial for consistent results _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n\n### Positive and Negative Controls\n- **Positive Controls**: Cells treated with a known effective drug (e.g., bortezomib) should show a consistent reduction in viability, with expected IC50 values that align with literature _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n- **Negative Controls**: Cells treated with DMSO alone should show minimal changes in viability, ideally close to 100% viability _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n- **Accepted Deviation**: A coefficient of variation (CV) of less than 20% is generally accepted for assay reproducibility, with more stringent targets (CV < 5%) recommended for optimal performance _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n\n### Recommendations to Increase/Ensure Reproducibility and Performance\n1. **Optimize Experimental Parameters**: Identify and correct for sources of variability, such as drug storage conditions and DMSO concentration controls _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n2. **Use Matched Controls**: Implement matched DMSO concentration controls for each drug dose to minimize solvent effects on viability _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n3. **Minimize Edge Effects**: Avoid using perimeter wells in 96-well plates to reduce variability due to evaporation and edge effects _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n4. **Standardize Protocols**: Establish standardized protocols for cell culture, drug treatment, and assay execution to enhance consistency across experiments _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n5. **Regularly Validate Assays**: Perform quality control metrics (e.g., Z-factor, signal window, CV) to ensure assay robustness and reliability _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n\nBy addressing these factors and implementing the recommendations, the reproducibility and performance of cell viability assays can be significantly improved."
        },
        {
          "question_id": 35,
          "question_text": "Define the specific endpoint(s) of the test system that you use for toxicity testing (e.g. cytotoxicity, cell migration, etc.). Indicate whether cytotoxicity is the primary endpoint. What are secondary/further endpoints? Also describe here potential reference/normalization endpoints (e.g. cytotoxicity, protein content, housekeeping gene expression) that are used for normalization of the primary endpoint.",
          "answer_text": "The primary endpoint of the assay is cytotoxicity, which is assessed through cell viability measurements using the resazurin reduction assay. This assay evaluates the metabolic activity of cells, providing an indication of cell viability after exposure to pharmaceutical agents such as bortezomib, cisplatin, and carboplatin _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n\nSecondary endpoints include various drug response metrics such as the half-maximal inhibitory concentration (IC50), growth rate inhibition concentration (GR50), maximum effect on viability at maximal drug concentration (Emax), area under the dose-response curve (AUC), and normalized drug response (NDR) _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n\nFor normalization of the primary endpoint (cytotoxicity), potential reference endpoints include matched DMSO concentration controls, which help account for the effects of the solvent on cell viability. Additionally, protein content or other housekeeping gene expressions could be utilized for normalization, although specific references to these normalization methods were not detailed in the provided context _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_."
        },
        {
          "question_id": 36,
          "question_text": "Define and describe the principle(s) of the analytical methods used. Provide here a general overview of the method\u2019s key steps (e.g. cells are fixed or not, homogenized sample or not, etc.), sufficient for reviewers/regulators to understand what was done, but not in all detail for direct repetition. If you have two or more endpoints (e.g. viability and neurite outgrowth), do you measure both in the same well, under same conditions in parallel, or independently of each other? For imaging endpoints: Explain in general how quantification algorithm or how semi-quantitative estimates are obtained and how many cells are imaged (roughly).",
          "answer_text": "The assay described in the document focuses on optimizing cell viability assays, specifically using the resazurin reduction assay to evaluate drug response in breast cancer cell lines (HCC38 and MCF7). The key principles of this analytical method involve measuring the metabolic activity of cells as an indicator of viability, where resazurin is reduced to resorufin in metabolically active cells.\n\n### Key Steps of the Method:\n1. **Cell Culture**: Human breast cancer cell lines (HCC38 and MCF7) are cultured in appropriate growth media supplemented with fetal bovine serum (FBS) under controlled conditions (37 \u00b0C, 5% CO2).\n\n2. **Cell Seeding**: Cells are plated in 96-well clear, flat-bottom microplates at a density of 7.5 \u00d7 10^3 cells per well in 100 \u00b5l of culture medium.\n\n3. **Drug Treatment**: After 24 hours of incubation to allow for cell attachment, cells are treated with various concentrations of pharmaceutical agents (e.g., bortezomib, cisplatin) for a specified duration (typically 24 hours).\n\n4. **Resazurin Addition**: Following drug treatment, a resazurin solution is added to each well. The cells are then incubated for an additional period (usually 4 hours) to allow for the reduction of resazurin to resorufin.\n\n5. **Measurement**: The absorbance or fluorescence of the wells is measured using a microplate reader. The amount of resorufin produced is proportional to the number of viable cells.\n\n6. **Data Analysis**: The percentage of cell viability is calculated based on the absorbance values, comparing treated cells to matched DMSO controls. Key metrics such as IC50 (half-maximal inhibitory concentration) and GR50 (growth rate inhibition) are derived from the dose-response curves.\n\n### Measurement of Endpoints:\nIn this assay, the primary endpoint measured is cell viability using the resazurin reduction assay. The viability and drug response metrics (IC50, GR50) are assessed independently based on the absorbance readings from the same wells, but the analysis focuses solely on viability.\n\n### Imaging and Quantification:\nWhile the document does not detail imaging endpoints, it mentions that absorbance and fluorescence are used for quantification. The quantification algorithm involves calculating the percentage of viability based on the difference in absorbance between treated and control wells. The number of cells imaged or analyzed is not specified, but it is implied that the entire well's response is measured, providing a comprehensive assessment of cell viability across the treatment conditions.\n\nOverall, the method is designed to be robust and reproducible, with careful consideration of experimental parameters to minimize variability and improve data quality _(Source: Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens)_."
        },
        {
          "question_id": 51,
          "question_text": "Describe possible variations, modifications and extensions of the test method: a) other endpoints, b) other analytical methods for same endpoint, c) other exposure schemes (e.g. repeated exposure, prolonged exposure, etc.), d) experimental variations (e.g. use of a specific medium, presence of an inhibitor or substrate that affects test outcome, etc.)",
          "answer_text": "The assay described in the document focuses on optimizing cell viability assays for cancer drug sensitivity screens. Here are possible variations, modifications, and extensions of the test method based on the provided context:\n\na) **Other Endpoints:**\n   - In addition to cell viability, other endpoints could include apoptosis (cell death), cell cycle distribution, and proteasome activity. These endpoints can provide insights into the mechanisms of drug action and cellular responses to treatment _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n\nb) **Other Analytical Methods for the Same Endpoint:**\n   - Besides the resazurin reduction assay, other analytical methods to assess cell viability include the MTT assay, ATP-based luminescence assays, and trypan blue exclusion assays. Each method has its own advantages and may yield different insights into cell viability and metabolic activity _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n\nc) **Other Exposure Schemes:**\n   - Variations in exposure schemes could include repeated exposure to drugs over several days, prolonged exposure beyond 72 hours, or varying the timing of drug administration (e.g., pre-treatment or post-treatment). These schemes can help assess the effects of drug scheduling on cell viability and drug resistance _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_.\n\nd) **Experimental Variations:**\n   - Experimental variations could involve using different types of growth media (e.g., serum-free media, media with varying FBS concentrations), the presence of specific inhibitors (e.g., proteasome inhibitors or other signaling pathway inhibitors), or substrates that may affect the assay outcome. Additionally, variations in cell seeding density, incubation times, and drug storage conditions can also impact the results and should be optimized for each specific experimental setup _(Source: Optimization of cell viability assays to improve replicability and reproducibility.pdf)_. \n\nThese modifications and extensions can enhance the robustness and applicability of the assay in different experimental contexts."
        }
      ]
    }
  ]
}